Programa de Pós-Graduação em Oncologia e Ciências Médicas - PPGOCM/NPO
URI Permanente desta comunidadehttps://repositorio.ufpa.br/handle/2011/4631
O Programa de Pós-Graduação em Oncologia e Ciências Médicas (PPGOCM) integra o Núcleo de Pesquisas em Oncologia (NPO) da Universidade Federal do Pará (UFPA). Trata-se do único centro de referência em pesquisa e formação de recursos humanos stricto sensu na área de oncologia na região Norte do Brasil. Os outros centros se concentram nas cidades do Rio de Janeiro e São Paulo.
Navegar
Navegando Programa de Pós-Graduação em Oncologia e Ciências Médicas - PPGOCM/NPO por Autor "HAGE, Pedro Antônio Mufarrej"
Agora exibindo 1 - 2 de 2
- Resultados por página
- Opções de Ordenação
Tese Acesso aberto (Open Access) Análise de citocinas no soro de pacientes com câncer gástrico(Universidade Federal do Pará, 2017-08-16) HAGE, Pedro Antônio Mufarrej; CALCAGNO, Danielle Queiroz; http://lattes.cnpq.br/1326603355062154Despite the reduction in the worldwide incidence of gastric cancer, this neoplasm remains the second largest cause of cancer death in the world. Late diagnosis occurs mainly due to the absence of symptoms or the presence of non-specific symptoms in the early stages of the disease. In this case, few effective therapeutic options are available, resulting in high rates of morbidity and mortality. The continuous study of new strategies for the early diagnosis, definition of the prognosis and identification of new therapeutic methods is of great interest in this neoplastic type. In the present study was quantified inflammatory proteins candidate to biomarkers in the serum of 19 patients with gastric adenocarcinoma before surgical resection and 13 healthy individuals as control. The methodology used for quantification of proteins was the MAGPIX system and panels of cancer biomarkers inventoried by the manufacturer (Bio-Plex Pro Human Pro-Cytokine, Chemokine and Growth Factors). In the comparison between patients with gastric adenocarcinoma and control group was observed the levels of IL-1β, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-12, IL-15, G-CSF, GM-CSF, IFN-γ, MIP1α, RANTES and VEGF were higher in serum of gastric adenocarcinoma patients. According clinicopathological characteristics, was observed elevated levels of IL-5, IL-7, IL-10 and IL-17A in diffuse-type gastric adenocarcinoma in relation intestinal-type. In addition, the association of the expression of the cytokines studied with overall survival (OS) and relapse-free survival (PFS) were performed using the KM Plotter Online Tool. Overexpression of G-CSF, GM-CSF and VEGF in tumor was associated with lower OS and PFS of gastric cancer patients. However, the overexpression of IL-10 was associated only with PFS. Thus, we can conclude that the IL-1β, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-12, IL-15, G-CSF, GM-CSF, IFN-γ, MIP1α, RANTES and VEGF cytokines are potential biomarkers of gastric cancer, and diffuse-type adenocarcinoma can related to a greater inflammatory response than intestinal-type. Survival analysis suggests that elevated levels of IL-10, G-CSF, GM-CSF and VEGF in serum are potential biomarkers of prognosis in gastric cancerpatients.Dissertação Acesso aberto (Open Access) Expressão dos genes TFF1 e TFF2 em adenocarcinoma gástrico(Universidade Federal do Pará, 2014-01-24) HAGE, Pedro Antônio Mufarrej; CALCAGNO, Danielle Queiroz; http://lattes.cnpq.br/1326603355062154; ASSUMPÇÃO, Paulo Pimentel de; http://lattes.cnpq.br/7323606327039876Gastric cancer remains a serious public health problem with high morbidity and mortality. Generally, the diagnoses occur in advanced disease when the available therapeutic options have limited effectiveness. Despite advances in the understanding of carcinogenesis of gastric adenocarcinoma, particularly on genetic and epigenetic mechanisms involved, the clinical aplicabilitadade such knowledge remains limited. In order to identify potential biomarkers in gastric cancer, we conducted a study using microarray comparing gene expression in gastric adenocarcinomas and paired samples of non- neoplastic gastric mucosa. Preliminary, the results showed significant differences in expression of 53 genes. Among these, the TFF1 and TFF2 genes were selected for validation of expression by real-time PCR in 78 additional samples. Expression of TFF1 and TFF2 were significantly reduced in samples of gastric adenocarcinoma when you compare the paired non-neoplastic tissues (p<0.05). Additionally, the TFF2 gene expression was significantly lower in the intestinal subtype than in the diffuse subtype. The expression of the two genes showed a strong correlation, the similar pattern of expression suggests that TFF1 and TFF2 may have common regulatory elements. This hypothesis is enhanced due to the small physical distances between them. The results suggest the involvement of TFF1 and TFF2 in gastric carcinogenesis and demonstrate the potential for clinical use of these genes as biomarkers and potential therapeutic targets in gastric adenocarcinoma.